Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
01/09/2026 16:57
BRIEF-Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA Sept 1 (Reuters) - Ocumension Therapeutics 1477.HK:
APPLICATION FOR DEXAMETHASONE INTRAOCULAR SUSPENSION ACCEPTED BY NMPA AS CLASS 4 CHEMICAL DRUG
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application